Purpose: To evaluate the efficacy and safety of oxaliplatin (L-OHP) in combination with leucovorin (LV)-modulated bolus plus infusional 5-fluorouracil (5-FU; de Gramont schedule) every 2 weeks in chemotherapy-naive patients with advanced colorectal cancer (CRC). Patients and Methods: Thirty-two patients (median age: 69 years) with histologically confirmed and two-dimensionally measurable metastatic CRC were enrolled. The patients’ performance status (WHO) was 0 in 14 (44%), 1 in 15 (47%), and 2 in 3 (9%) patients. Twenty (62.5%) patients had at least two metastatic sites. LV was administered at a dose of 200 mg/m2/day as a 2-hour intravenous infusion, followed by 5-FU as an intravenous bolus at the dose of 400 mg/m2 and then, as a 22-hour continuous infusion at the dose of 600 mg/m2/day for 2 consecutive days. L-OHP was administered on day 1 at the dose of 85 mg/m2 as a 2-hour infusion in parallel with LV but using different infusion lines. Treatment was administered every 2 weeks. Results: In an intention-to-treat analysis, 2 (6.2%) complete and 9 (28%) partial responses (28%; odds ratio 34.2%; 95% confidence interval 17.92–50.83%) were achieved while 8 (25%) patients had stable disease and 13 (41%) progressive disease. The median duration of response was 5 months, but the median time to progression has not yet been reached. After a median follow-up period of 11 months, the median survival has not yet been attained, but the projected probability for 1-year survival was 72%. Grade 3/4 neutropenia occurred in 16 (50%) patients while 1 (3%) of them developed febrile neutropenia. There was no treatment-related death. Peripheral neuropathy grade 2 and ≧3 occurred in 5 (16%) and 7 (21%) patients, respectively. Conclusions: The bimonthly administration of L-OHP in association with LV-modulated bolus plus infusional 5-FU (‘de Gramont’ regimen) is a well-tolerated and effective front-line treatment for metastatic CRC.

Keywords:
Colorectal cancer, 5-Fluorouracil, Oxaliplatin
1.
Piedbois P, Buyse M, Rustum Y, et al, for the Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer – Evidence in terms of response rate. J Clin Oncol 1992;10:896–903.
2.
Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301–308.
3.
de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. J Clin Oncol 1997;15:808–815.
4.
Bleiberg H: Oxaliplatin (L-OHP): A new reality in colorectal cancer. Br J Cancer 1998;77 (suppl 4):1–3.
5.
Cvitkovic E: Ongoing and unsaid on oxaliplatin: The hope. Br J Cancer 1998;77(suppl 4):8–11.
6.
Woynarowski JM, Chapman WG, Napier C, et al: Oxaliplatin effects on naked and intracellular DNA. Proc Am Assoc Cancer Res 1997;38:311.
7.
Scheeff ED, Howell SB: Computer modeling of the primary cisplatin and oxaliplatin DNA adducts and relevance to mismatch repair recognition. Proc Am Assoc Cancer Res 1998;39:158.
8.
Becouarn Y, Ychou M, Ducreux M, et al: Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: Preliminary activity/toxicity report. Am Soc Clin Oncol 1997;16:229.
9.
Diaz-Rubio E, Sastre J, Zaniboni A, et al: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol 1998;9:105–108.
10.
Levi F, Perpoint B, Garufi C, et al: Oxaliplatin activity against metastatic colorectal cancer. A phase II study of five-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993;9(29A):1280–1284.
11.
Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95–98.
12.
Mathe G, Kidani Y, Triana K, et al: A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (L-OHP). Biomed Pharmacother 1986;40:372–376.
13.
Extra JM, Espie M, Calvo F, et al: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990;25:299–303.
14.
Raymond E, Djelloul C, Buquet-Fagot F, et al: Oxaliplatin (L-OHP) and cisplatin (CDDP) in combination with 5-FU, specific thymidate synthase (TS) inhibitors (AG 337, ZD 1694) and topoisomerase I (Topo-1) inhibitors (SN 38, CPT-11) in human colonic, ovarian and breast cancers. Am Assoc Cancer Res 1996;291:37.
15.
de Gramont A, Vignoud J, Tournigand C, et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214–219.
16.
Giacchetti S, Zidani R, Perpoint B, et al: Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 1997;16:229.
17.
de Gramont A, Gastiaburu J, Tournigand C, et al: Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48-hour infusion in pretreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 1994;13:220.
18.
Levi F, Misset JL, Brienza S, et al: A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 1992;69:893–900.
19.
Evaluation of the cancer patient and the response to treatment; in Monfardini S, Brunner K, Crowther D, et al (eds): UICC Manual of Adult and Paediatric Medical Oncology. Berlin, Springer, 1987, pp 22–38.
20.
Ajani JA, Welch SR, Raber MN, et al: Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990;8:147–159.
21.
Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1959;53:457–481.
22.
Cox DR: The Analysis of Binary Data. London, Methnen, 1970.
23.
Levi F, Zidani R, Misset JL, et al: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. Lancet 1997:350:681–686.
24.
Levi F, Zidani R, Vannetzel JM, et al: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial. J Natl Cancer Inst 1994;86:1608–1617.
25.
Figer A, Louvet C, Homerin M, et al: Analysis of prognostic factors of overall survival (OS) in the randomized trial of bimonthly leucovorin and 5-fluorouracil regimen (LV5FU2) with or without oxaliplatin (OXA) in advanced colorectal cancer (ACC) (abstract 918). Proc Am Soc Clin Oncol 1999;18:239a.
26.
Comba ZA, Blajman C, Richardet E, et al: Bimonthly oxaliplatin (L-OHP) with (A) or without (B) fluorouracil (FU) and leucovorin (FA): Proven evidence of synergism in a phase II randomized trial (abstract 953). Proc Am Soc Clin Oncol 1999;18:243a.
27.
Sun Y, Guan ZZ, Jin LM, et al: A multicenter randomized phase II trial of oxaliplatin alone and in combination in patients with advanced colorectal cancer in China (abstract 979). Proc Am Soc Clin Oncol 1999;18:255a.
28.
de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–2947.
29.
Douillard YJ, Cunningham D, Roth DA, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomized trial. Lancet 2000;355:1041–1047.
30.
Tournigand C, Louvet C, André T, et al: FOLFIRI followed vs FOLFOX or FOLFOX followed by FOLFIRI in metastatic colorectal cancer: Which is the best sequence safety and preliminary efficacy results of a randomized phase III study (abstract 949). Proc Am Soc Clin Oncol 2000;19:245a.
31.
Recchia F, de Filippis S, Rosselli M, et al: Randomized phase II study of oxaliplatin (OX) or CPT-11 (CPT) combined with bimonthly leucovorin (L) and 5-fluorouracil (5-FU) in metastatic colorectal cancer (MCC): Preliminary report (abstract 1049). Proc Am Soc Clin Oncol 2000;19:269a.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.